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Abstract
AIM: To study the different endocrine cell types in the 
oxyntic mucosa of patients with irritable bowel syn-
drome (IBS).
METHODS: Seventy-six patients with IBS were in-
cluded in the study (62 females and 14 males; mean 
age 32 years, range 18-55 years), of which 40 also 
fulfilled the Rome Ⅲ criteria for functional dyspepsia 
(FDP). Of the entire IBS cohort, 26 had diarrhea as 
the predominant symptom (IBS-D), 21 had a mixture 
of diarrhea and constipation (IBS-M), and 29 had con-
stipation as the predominant symptom (IBS-C). Forty-
three age and sex-matched healthy volunteers without 
any gastrointestinal complaints served as controls. The 
patients were asked to complete the Birmingham IBS 
symptom questionnaire. Both the patients and controls 
underwent a standard gastroscopy, during which three 
biopsy samples were taken from the corpus. Sections 
from these biopsy samples were immunostained using 
the avidin-biotin complex (ABC) method, for ghrelin, 
serotonin, somatostatin and histamine. The densities of 
these cell types and immunoreactivity intensities were 
quantified using computerized image analysis with 
Olympus cellSens imaging software (version 1.7).
RESULTS: The densities of the ghrelin cells in the con-
trol, IBS-total, IBS-D, IBS-M and IBS-C groups were 
389 (320, 771), 359 (130, 966), 966 (529, 1154), 358 
(120, 966) and 126 (0, 262) cells/mm2, respectively. 
There was a significant difference between the tested 
groups (P < 0.0001). Dunn’s multiple comparison test 
showed that the ghrelin cell density was significantly 
higher in IBS-D and lower in IBS-C than in the controls 
(P = 0.03 and 0.0008, respectively). The ghrelin cell 
density in patients with both IBS and FDP was 489 (130, 
966), and in those with IBS only 490 (130, 956). There 
was no statistical significant difference between these 
2 groups of patients (P = 0.9). The immunoreactiv-
ity intensity did not differ between any of the groups 
(P = 0.6). The diarrhea score of the Birmingham IBS 
symptom questionnaire was significantly positively cor-
related with ghrelin cell density (r  = 0.65; P < 0.0001) 
and significantly inversely correlated with that of con-
stipation (r  = 90.69; P < 0.0001). The densities of the 
serotonin cells were 63 (51, 82), 51 (25, 115), 120 (69, 
128), 74 (46, 123) and 40 (0, 46) cells/mm2 in the con-
trol, IBS-total, IBS-D, IBS-M and IBS-C groups, respec-
tively. A statistically significant difference was found 
between the tested groups (P < 0.0001). Posttest 
revealed that serotonin cell density was significantly 
higher in IBS-D and lower in IBS-C than in controls (P 
= 0.02 and 0.004, respectively), but did not differ in 
the IBS-total and IBS-M groups from that in controls (P 
= 0.5 and 0.4, respectively). The serotonin cell density 
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in patients with both IBS and FDP was 62 (25, 115) 
and in those with IBS only 65 (25, 123). There was 
no statistically significant difference between these 
2 groups of patients (P = 1). The immunoreactivity 
intensity of serotonin did not differ significantly be-
tween any of the groups (P = 0.0.9). The serotonin 
cell density was significantly positively correlated with 
the diarrhea score of the Birmingham IBS symptom 
questionnaire (r  = 0.56; P < 0.0001) and significantly 
inversely correlated with that of constipation (r  = 0.51; 
P < 0.0001). The densities of the somatostatin cells 
were 97 (72, 126), 72 (0, 206), 29 (0, 80), 46 (0, 103) 
and 206 (194, 314) cells/mm2 in the control, IBS-total, 
IBS-D, IBS-M and IBS-C groups, respectively (Figures 
7 and 8). There was a statistically significant differ-
ence between the controls and the IBS subgroups (P < 
0.0001). The density of somatostatin cells was signifi-
cantly lower in the IBS-D and IBS-M groups but higher 
in IBS-C patients than in the controls (P < 0.01, P = 
0.02, and P = 0.0008, respectively). The somatostatin 
cell density in patients with both IBS and FDP was 86 
(0-194), and in those with IBS only 110 (0-206). There 
was no statistically significant difference between 
these 2 groups of patients (P = 0.6). There was no 
significant difference in somatostatin immunoreactiv-
ity intensity between the controls. The diarrhea score 
of the Birmingham IBS symptom questionnaire was 
inversely correlated with somatostatin cell density (r  = 
0.38; P = 0.0007) and was positively correlated with 
that of constipation (r  = 0.64; P < 0.0001).
CONCLUSION: The finding of abnormal endocrine 
cells in the oxyntic mucosa shows that the endocrine 
cell disturbances in IBS are not restricted to the intes-
tine. Furthermore, it appears that ghrelin, serotonin 
and somatostatin in the oxyntic mucosa of the stomach 
may play an important role in the changing stool habits 
in IBS through their effects on intestinal motility.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: There are four endocrine cell types in the ox-
yntic mucosa of the stomach: ghrelin, serotonin, soma-
tostatin and histamine-containing (enterochromaffin-
like) cells. These cells regulate several functions that 
are disturbed in patients with irritable bowel syndrome 
(IBS), such as motility and visceral sensation. Of all 
these cell types, ghrelin cells are the only endocrine cell 
type that has been studied in IBS patients. The present 
study investigated all the oxyntic mucosa endocrine cell 
types and reported several abnormalities that can shed 
light on the pathophysiology of IBS.
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INTRODUCTION
The gastrointestinal endocrine cells are scattered among 
the mucosal epithelial cells lining the gastrointestinal lu-
men[1-4]. These cells can be divided into several types ac-
cording to the hormone they produce. They have special-
ized microvilli that project into the lumen and function as 
sensors of  the luminal contents, and respond by releasing 
their hormones into the lamina propria, where they act 
locally (paracrine mode) or via the bloodstream (endocrine 
mode)[5-14]. These cells interact and integrate with each 
other, with the enteric nervous system, and with afferent 
and efferent nerve fibers from the autonomic nervous 
system[1-4]. There are four types of  endocrine cell in the 
oxyntic mucosa of  the stomach: ghrelin, serotonin, soma-
tostatin and histamine-containing (enterochromaffin-like) 
cells[1,2].
Irritable bowel syndrome (IBS) is a common disorder 
that affects 10%-20% of  the population in the Western 
world, producing symptoms of  abdominal pain/discom-
fort and altered bowel habits[4]. The findings of  labora-
tory tests, endoscopic examinations and radiological tests 
are normal in these patients and the diagnosis is based 
mainly on symptom assessment[4]. Endocrine cell abnor-
malities have been reported in both the small and large 
intestines of  IBS patients[15-29], but ghrelin cells are the 
only endocrine cells of  the oxyntic mucosa of  the stom-
ach that have been investigated thus far[30].
The aim of  this study was to determine whether there 
are abnormalities in the densities and immunoreactivity 
intensities of  all of  the endocrine cell types in the oxyntic 
mucosa of  the stomach in a cohort of  patients with IBS, 
including all IBS subtypes: those with diarrhea, constipa-
tion or a mixture of  both as the predominant symptom 
(IBS-D, IBS-C and IBS-M, respectively).
MATERIALS AND METHODS
Patients and controls
Seventy-six patients who fulfilled the Rome Ⅲ criteria for 
IBS were included in the study (62 females and 14 males; 
mean age 32 years, range 18-55 years)[31,32], of  which 40 
also fulfilled the Rome Ⅲ criteria for functional dyspep-
sia (FDP). None of  the patients had used proton pump 
inhibitor medication in the last 6 mo. Of  the entire IBS 
cohort, 26 had IBS-D, 21 had IBS-M, and 29 had IBS-C. 
All of  the patients underwent a complete physical ex-
amination and were investigated by way of  blood tests 
to exclude inflammatory, liver, endocrine and any other 
systemic diseases. Moreover, they were submitted to a 
colonoscopy with segmental biopsies, which revealed the 
presence of  a normal terminal ileum, colon and rectum 
in all cases.
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Forty-three age and sex-matched healthy volunteers 
without any gastrointestinal complaints were recruited as 
controls via local announcements at our hospitals and in 
the local newspapers (32 females and 11 males; mean age 
40 years, range 20-58 years).
The study was approved by the Regional Committee 
for Medical and Health Research Ethics West, Bergen, 
Norway. All subjects provided both oral and written con-
sent to participate.
Symptom assessment
The patients were asked to complete the Birmingham 
IBS symptom questionnaire, a disease-specific tool for 
assessing the symptoms of  patients with IBS. Its dimen-
sions have good reliability, external validity and sensitiv-
ity[33]. The questionnaire comprises 11 questions related 
to the frequencies of  IBS-related symptoms. All of  the 
questions are measured on a 5-point Likert scale. The 
questionnaire comprises three underlying dimensions: 
pain, diarrhea and constipation[33].
Gastroscopy, histopathology and 
immunohistochemistry
Both the patients and controls underwent a standard 
gastroscopy after an overnight fast, during which three 
biopsy samples were taken from the corpus (major cur-
vature) and two from the antrum. The two antral biopsy 
samples were used in a rapid urease test for Helicobacter 
pylori (H. pylori) infection (HelicotecUT Plus, Strong 
Biotech, Taipei, Taiwan). The corpus biopsy samples 
were fixed overnight in 4% buffered paraformaldehyde, 
embedded in paraffin, and then sectioned at a thickness 
of  5 µm. The sections were stained with hematoxylin-
eosin and immunostained using the avidin-biotin com-
plex (ABC) method with a VECTASTAIN ABC kit 
and 3,3’-diaminobenzidine peroxidase substrate (DAB) 
as the chromogen (Vector Laboratories, Burlingame, 
CA, United States). The primary antibodies used were 
monoclonal mouse anti-N-terminus of  human ghre-
lin (code 2016003, Millipore, Temecula, CA, United 
States), monoclonal mouse antihuman serotonin (clone 
5HT-H209, code M0758, Dako, Glostrup, Denmark), 
polyclonal rabbit antisynthetic cyclic (1-14) somatostatin 
(code A0566, Dako), and monoclonal mouse antihista-
mine-hexamethylene diisocyanate-BSA (code 2273835, 
Millipore). The sections were incubated at room tem-
perature for 2 h with the primary antibodies diluted to 
1:200. They were then washed in phosphate-buffered 
saline (PBS, pH = 7.4) and incubated with biotinylated 
swine antimouse IgG (in the case of  monoclonal anti-
bodies) or goat antirabbit IgG (in the case of  polyclonal 
antibodies), both diluted to 1:200, for 30 min at room 
temperature. After washing the slides in PBS, the sec-
tions were incubated for 30 min with peroxidase-labeled 
ABC diluted to 1:100, and then immersed in DAB, fol-
lowed by counterstaining with hematoxylin.
Computerized image analysis
Quantification of  the endocrine cells density and im-
munoreactivity intensity was achieved using Olympus 
cellSens imaging software (version 1.7). The microscope 
(BX 43, Olympus, Oslo, Norway) was equipped with 
built-in Koehler illumination for transmitted light, a light-
intensity manager switch, a high-color-reproductivity 
LED light source, a 6-V/30-W halogen bulb and a digital 
camera (DP 26, Olympus). The number of  immunoreac-
tive cells, the area of  epithelial cells, and the immunoreac-
tivity intensity were measured. The number of  immuno-
reactive cells in each field and the area of  epithelium were 
counted manually, while the immunoreactivity intensity 
in each field was measured using an automatic threshold 
setting. A × 40 objective was used, which resulted in each 
frame (field) on the monitor representing a tissue area of  
0.035 mm2. Measurements were made in ten randomly 
chosen fields in each individual section. Immunostained 
sections from the IBS patients and controls were coded 
and mixed, and measurements were made by the same 
person (M.E.-S.) who was blind to the identity of  the 
patient to whom the tissue sections belonged. The en-
docrine cell density is expressed as cells/mm2 epithelium 
and the immunoreactivity intensity is given in arbitrary 
units (a.u.).
Statistical analysis
Differences in the gender distribution and the occurrence 
of  H. pylori infection between the patients and controls 
were tested using Fisher’s exact test. Differences in the 
age distribution were tested using the Mann-Whitney 
nonparametric test. Differences between the control, all 
IBS patients combined (IBS-total), IBS-D, IBS-M and 
IBS-C groups were tested using the Kruskal-Wallis non-
parametric test with Dunn’s posttest. Correlations were 
analyzed using Spearman’s nonparametric test. The data 
are presented as median and interquartile (25th and 75th 
percentile) values and differences with P < 0.05 were 
considered statistically significant.
RESULTS
Patients and controls
The sex and age distributions did not differ significantly 
between the patients and controls (P = 0.196 and P = 
0.360, respectively). The incidence of  H. pylori infection 
did not differ between the patients (n = 3) and controls 
(n = 2, P = 1.0). The total score for the Birmingham IBS 
symptom questionnaire for the entire patient cohort (i.e., 
IBS-total) was 21.5 ± 0.7. The scores on the pain, diar-
rhea and constipation dimensions were 7.2 ± 0.4, 6.6 ± 
0.4, and 7.2 ± 0.4, respectively.
Gastroscopy, histopathology and 
immunohistochemistry
The esophagus was macroscopically normal while the 
stomach and duodenum were both macroscopically and 
microscopically normal in both the patients and controls. 
Immunoreactive cells were found in the stomach oxyntic 
mucosa of  both the patients and controls, and were ei-
ther basket or flask-shaped, sometimes with a long basal 
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ence between the tested groups (P < 0.0001). Dunn’s mul-
tiple comparison test showed that the ghrelin cell density 
was significantly higher in IBS-D and lower in IBS-C 
than in the controls (P = 0.03 and 0.0008, respectively). 
The ghrelin cell density in patients with both IBS and 
FDP was 489.0 ± 68.1, and in those with IBS only 490.1 
± 73.5. There was no statistically significant difference 
between these 2 groups of  patients (P = 0.9). The im-
munoreactivity intensity did not differ between any of  
the groups, being 133 (131, 134), 131 (125, 133), 129 (125, 
133), 132 (124, 134) and 130 (123, 133) a.u. in the con-
trol, IBS-total, IBS-D, IBS-M and IBS-C groups, respec-
tively (P = 0.6). The diarrhea score of  the Birmingham 
IBS symptom questionnaire was significantly positively 
cytoplasmic process. There were insufficient histamine 
cells in the biopsy samples studied to allow any reliable 
quantification thereof.
Computerized image analysis
The results of  the quantification of  different endocrine 
cell types in the oxyntic mucosa of  the stomach in IBS 
subtypes are given in Table 1.
Ghrelin: The densities of  the ghrelin cells in the control, 
IBS-total, IBS-D, IBS-M and IBS-C groups were 389 (320, 
771), 359 (130, 966), 966 (529, 1154), 358 (120, 966) and 
126 (0, 262) cells/mm2, respectively (Figures 1 and 2). The 
Kruskal-Wallis test revealed a statistically significant differ-
Figure 1  Ghrelin cell densities (A) and ghrelin immunoreactivity intensities (B) in the oxyntic mucosa of the stomach of controls and IBS-total, IBS-D, 
IBS-M and IBS-C patients. aP < 0.05, and dP < 0.01 vs controls. IBS: Irritable bowel syndrome; IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients 
with diarrhea as the predominant syndrome; IBS-M: Patients with both diarrhea and constipation; IBS-C: Patients with constipation as the predominant syndrome. 
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Table 1  The densities of different endocrine cell types in controls, IBS-total, IBS-D, IBS-M and IBS-C
Endocrine cell type Controls IBS-total IBS-D IBS-M IBS-C
Ghrelin   389 (320, 771)   359 (130, 966)      996 (529, 1154)a  358 (120, 966) 126 (0, 262)c
Serotonin 63 (51, 82)   51 (25, 115)  120 (69, 128)a  74 (47, 123) 40 (0, 46)b
Somatostatin   97 (72, 126) 72 (0, 206) 29 (0, 80)b 46 (0, 103)a     206 (194, 314)c
Values are expressed as median and interquartile (25th and 75th). aP < 0.05, bP < 0.01 and cP < 0.0001 vs controls. IBS: Irritable bowel syndrome; IBS-total: All 
patients with irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-M: Patients with both diarrhea and constipation; 
IBS-C: Patients with constipation as the predominant syndrome.
CBA
20 mm20 mm20 mm
Figure 2  Ghrelin-immunoreactive cells in a control subject (A), a patient with IBS-D (B), and a patient with IBS-C (C). IBS: Irritable bowel syndrome; IBS-D: 
Patients with diarrhea as the predominant syndrome; IBS-C: Patients with constipation as the predominant syndrome.
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correlated with ghrelin cell density (r = 0.65; P < 0.0001) 
and significantly inversely correlated with that of  consti-
pation (r = -0.69; P < 0.0001; Figure 3).
Serotonin: The densities of  the serotonin cells were 63 
(51, 82), 51 (25, 115), 120 (69, 128), 74 (46, 123) and 40 
(0, 46) cells/mm2 in the control, IBS-total, IBS-D, IBS-M 
and IBS-C groups, respectively. The Kruskal-Wallis test 
revealed a statistically significant difference between the 
tested groups (P < 0.0001). Dunn’s posttest revealed that 
serotonin cell density was significantly higher in IBS-D 
and lower in IBS-C than in controls (P = 0.02 and 0.004, 
respectively; Figures 4 and 5), but did not differ in the 
IBS-total and IBS-M groups from that in controls (P = 
0.5 and 0.4, respectively). The serotonin cell density in 
patients with both IBS and FDP was 62.0 ± 6.5, and in 
those with IBS only 65.2 ± 9.5. There was no statistically 
significant difference between these 2 groups of  patients 
(P = 1). The immunoreactivity intensity of  serotonin did 
not differ significantly between any of  the groups, being 
107 (103, 110), 106 (103, 107), 120 (69, 128), 106 (103, 
108) and 107 (101,110) a.u. in the control, IBS-total, 
IBS-D, IBS-M and IBS-C groups, respectively (P = 0.0.9). 
The serotonin cell density was significantly positively cor-
related with the diarrhea score of  the Birmingham IBS 
symptom questionnaire (r = 0.56; P < 0.0001) and signifi-
cantly inversely correlated with that of  constipation (r = 
-0.51; P < 0.0001; Figure 6).
Somatostatin: The densities of  the somatostatin cells 
were 97 (72, 126), 72 (0, 206), 29 (0, 80), 46 (0,103) and 
206 (194, 314) cells/mm2 in the control, IBS-total, IBS-D, 
IBS-M and IBS-C groups, respectively (Figures 7 and 8). 
The Kruskal-Wallis test indicated a statistically significant 
difference between the controls and the IBS subgroups (P 
< 0.0001). The density of  somatostatin cells was signifi-
cantly lower in the IBS-D and IBS-M groups, but higher 
in IBS-C patients than in the controls (P < 0.01, P = 0.02 
and P = 0.0008, respectively). The somatostatin cell den-
sity in patients with both IBS and FDP was 86.3 ± 19.3, 
and in those with IBS only 110.1 ± 24.1. There was no 
statistical significantly difference between these 2 groups 
Figure 3  Correlations of ghrelin cell density with diarrhea (A) and constipation (B) scores as assessed by the Birmingham irritable bowel syndrome symp-
tom questionnaire. IBS: Irritable bowel syndrome. 
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Figure 4  Serotonin cell densities (A) and serotonin immunoreactivity intensities (B) in IBS-total, IBS-D, IBS-M and IBS-C patients. aP < 0.05, bP < 0.01 vs 
controls. IBS: Irritable bowel syndrome; IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-M: Pa-
tients with both diarrhea and constipation; IBS-C: Patients with constipation as the predominant syndrome. 
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of  patients (P = 0.6). There was no significant difference 
in somatostatin immunoreactivity intensity between the 
controls (111; 109, 113 a.u.) and the IBS-total (112; 111, 
112 a.u.), IBS-D (111; 109, 113 a.u.), IBS-M (113; 110, 
113 a.u.), and IBS-C (113; 111, 113 a.u.) patients (P = 0.9). 
The diarrhea score of  the Birmingham IBS symptom 
questionnaire was inversely correlated with somatostatin 
cell density (r = -0.38; P = 0.0007) and was positively cor-
related with that of  constipation (r = 0.64; P < 0.0001; 
Figure 9).
DISCUSSION
The findings of  the present study show that the densities 
Figure 5  Serotonin cells in the oxyntic mucosa of the stomach of a control subject (A), a patient with IBS-D (B), and a patient with IBS-C (C). IBS: Irritable 
bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-C: Patients with constipation as the predominant syndrome.
Figure 6  Correlations of serotonin cell density with diarrhea (A) and constipation (B) scores as assessed by the Birmingham irritable bowel syndrome 
symptom questionnaire. IBS: Irritable bowel syndrome. 
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Figure 7  Somatostatin cell densities (A) and somatostatin immunoreactivity intensities (B) in IBS-total, IBS-D, IBS-M and IBS-D patients. The symbols are the 
same as in Figures 1 and 4. IBS: Irritable bowel syndrome; IBS-total: All patients with irritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syn-
drome; IBS-M: Patients with both diarrhea and constipation; IBS-C: Patients with constipation as the predominant syndrome. aP < 0.05, bP < 0.01 and dP < 0.01 vs controls.
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of  the three main types of  endocrine cells in the oxyntic 
mucosa of  the stomach, namely ghrelin, serotonin and 
somatostatin cells, are abnormal in IBS patients. How-
ever, the nature of  these abnormalities differ with the 
IBS subtype, whereby the densities of  the ghrelin and se-
rotonin cells are high in IBS-D but low in IBS-C, and the 
density of  somatostatin cells is low in IBS-D and IBS-M 
but high in IBS-C. As there is no difference in the endo-
crine cells densities between patients with IBS/FDP and 
patients with IBS only, the abnormalities seen in these 
cells are most probably caused by IBS. The immunore-
activity intensity of  ghrelin, serotonin and somatostatin 
in IBS patients did not differ from that of  controls. This 
indicates that the cellular content of  these hormones in 
IBS patients is not affected relative to controls, which is 
an important finding given that the cellular content of  a 
hormone reflects its cellular synthesis and release.
Abnormalities in the endocrine cells in both the small 
and large intestines have been reported in patients with 
IBS[15-17,20-30,34,35]. In the small intestine, the duodenal cell 
densities of  gastric inhibitory peptide (GIP), secretin, 
cholecystokinin (CCK) and somatostatin, and the ileal 
cell densities of  serotonin and peptide YY (PYY) were 
found to be abnormal[16,18]. In the large intestine, colonic 
serotonin and PYY, and rectal serotonin, PYY, entero-
glucagon and somatostatin cell densities have all been 
found to be affected[17,19,20]. Postinfectious IBS has been 
reported to be associated with elevated numbers of  duo-
denal CCK cells and rectal serotonin cells, but decreased 
numbers of  duodenal serotonin cells[15,22,24,26,29,35]. The 
present observation of  abnormal densities of  gastric en-
docrine cells suggests that the endocrine cell disturbanc-
es occur throughout the gastrointestinal tract of  patients 
with IBS.
The present findings that ghrelin cell density was high 
in IBS-D and low in IBS-C confirm the results of  an 
earlier study involving another cohort of  IBS patients[30]. 
The present study also found that the ghrelin cell den-
sity was not affected in IBS-M. As well as regulating the 
release of  growth hormone and roles in appetite and en-
ergy metabolism[36-39], ghrelin accelerates gastric and small 
and large intestine motility[40-51]. Ghrelin cell density was 
found in the present study to be strongly positively corre-
lated with the degree of  diarrhea and inversely correlated 
with the degree of  constipation. It is thus conceivable 
that changes in ghrelin cell density play a role in the de-
velopment of  diarrhea and constipation in IBS patients.
Serotonin stimulates colonic motility and accelerates 
transit through the small and large intestines[52-60]. In the 
present study, the serotonin cell density was higher in 
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Figure 8  Somatostatin cells in the oxyntic mucosa of the stomach of a control subject (A), a patient with IBS-D (B), and a patient with IBS-C (C). IBS: Ir-
ritable bowel syndrome; IBS-D: Patients with diarrhea as the predominant syndrome; IBS-C: Patients with constipation as the predominant syndrome.
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Figure 9  Correlations of somatostatin cell density with diarrhea (A) and constipation (B) scores as assessed by the Birmingham irritable bowel syndrome 
symptom questionnaire. IBS: Irritable bowel syndrome. 
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IBS-D and lower in IBS-C compared to healthy controls 
and unchanged in IBS-M. Moreover, the serotonin cell 
density was positively correlated with the degree of  diar-
rhea and inversely correlated with the degree of  consti-
pation. Therefore, similar to ghrelin, serotonin seems to 
play a role in the development of  both diarrhea and con-
stipation in IBS patients.
Somatostatin inhibits intestinal contraction and gut 
exocrine and neuroendocrine secretion[2,4]. In the pres-
ent study, the somatostatin cell density was low in both 
IBS-D and IBS-M and high in IBS-C. Furthermore, the 
somatostatin cell density was inversely correlated with the 
diarrhea score and positively correlated with the constipa-
tion score (both assessed by the Birmingham IBS symp-
tom questionnaire). It is therefore possible that changes 
in the somatostatin cell density also play a considerable 
role in the development of  both diarrhea and constipa-
tion in IBS patients.
In conclusion, the results of  the present study show 
that the endocrine cells in the oxyntic mucosa of  the 
stomach in IBS patients are affected and thus that the 
endocrine cell disturbances observed in IBS are not re-
stricted to the intestine. Furthermore, it appears from the 
present findings that ghrelin, serotonin and somatostatin 
in the oxyntic mucosa of  the stomach may play an im-
portant role in the change in stool habits in IBS via their 
effects on intestinal motility. These observations shed 
light on the pathophysiology of  IBS and agonists and/or 
antagonists to the hormones described can probably be 
used in the near future in the treatment of  patients with 
IBS.
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